Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2016

View Archived Issues

FAK inhibition shows potential as a target for combination with immunotherapy

miR-1246 and miR-1290 as novel therapeutic targets and biomarkers of disease progression

University of Vermont and State Agricultural College patents autophagy inhibitors

Auspex Pharmaceuticals discloses cytochrome P450 CYP11B1 inhibitors

Novira Therapeutics describes antiviral agents

Madrigal Pharmaceuticals, Synta Pharmaceuticals complete merger

EMA committee recommends approval of Onivyde in E.U.

EMA's CHMP grants positive opinion to Cabometyx in RCC

XBiotech reports progress for Xilonix in U.S. and E.U.

EMA committee supports approval of Eisai's Kisplyx

Euroscreen opens IND for three phase II studies of ESN-364

IDO activity shows promise as a biomarker for tuberculosis

FDA grants QIDP and fast track designations to MCB-3837 for C. difficile infection

Roche updates pipeline progress of second quarter 2016

Increased sCD74 serum levels correlate with severity of lung injury

miR-877-3p as a potential new fibrosis marker for predicting prognosis

Functional rs353292 polymorphism in the flanking region of miR-143/145 as risk factor for CRC

InflaRx raises funds in series C financing

VIB and Oxford Nanopore Technologies collaborate on DNA sequencing technology

Almirall and Patagonia Pharmaceuticals enter licensing agreement

EMA's CHMP adopts positive opinion on type II variation application for Gilead's Truvada

Grant supports work at The Scripps Research Institute on stem cells for Parkinson's disease

Sunovion reports results of SUN-101/eFlow phase III study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...